Northland Securities reiterated their buy rating on shares of ImmuPharma PLC (LON:IMM) in a report released on Thursday morning. They currently have a GBX 181 ($2.39) price objective on the stock.

Separately, Northland Capital Partners restated a buy rating and set a GBX 181 ($2.39) price objective on shares of ImmuPharma PLC in a research note on Thursday, September 21st.

Shares of ImmuPharma PLC (IMM) traded down GBX 0.05 ($0.00) during midday trading on Thursday, reaching GBX 95.95 ($1.27). 538,325 shares of the company’s stock traded hands, compared to its average volume of 320,998. ImmuPharma PLC has a twelve month low of GBX 31.44 ($0.41) and a twelve month high of GBX 103.50 ($1.37).

WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at

ImmuPharma PLC Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.